Personale docente

Personal details

First Name: Susanna 

Last Name: Esposito

Place/date of birth: Milan/5 September 1971.

Nationality: Italian.

Marital Status: Married, a son.

Tax code Code: SPSSNN71P45F205V

E-mail address: susannamariaroberta.esposito@unipr.it

Address: University Hospital of Parma, Maternal and Child Department.

University of Parma, Department of Medicine and Surgery.

Building 15, Floor 2 - Via Gramsci 14; 43126 Parma-Italy.

Telephone number: +39 0521 704790.

Languages: Italian (mother tongue); English (C2); Spanish (B2).

Web site: www.susannaesposito.it

Current position

Full Professor in Pediatrics (scientific/disciplinary sector MED/38: General and Specialized Pediatrics) at the Faculty of Medicine and Surgery of the University of Parma, Italy (since September 1, 2019).

Director of Pediatric Clinic in Maternal and Child Department -Azienda Ospedaliero- Universitaria di Parma (since November 1, 2019).

Director of the School of Specialisation in Paediatrics at the University of Parma, Parma, Italy (since 10 February 2020)

Pre-university and university education

• Classical high school diploma obtained in 1989 (Liceo ginnasio Zaccaria, Milan).

• University education at the Faculty of Medicine of the University of Milan.

University internships

• Institute of Human Physiology (Prof. Emilio Agostoni): academic year 1991-92.

• Pediatric Clinic I (Prof. Paolo Careddu): academic years 1992-93 and 1993-94.

• Pediatric Clinic IV (Prof. Nicola Principi): academic year 1994-95.

Pre-graduate study awards

• Exemption fees for merit throughout the university course.

Degree in medicine and surgery

• At the University of Milan on 27 July 1995, with 110/110 marks and honors. Thesis title: "Evaluation of the synthesis of IgE in relation to the progression of HIV infection in children" (Supervisor: Prof. Nicola Principi).

Specializations
• In Pediatrics (1999), at the School of Specialization in Pediatrics III of the University of Milan.
• In Infectious Diseases (2006), at the School of Specialization in Infectious Diseases of the University of Milan.

Scientific activity

The scientific activity began during university studies at the Pediatric IV Clinic of the University of Milan with research on pediatric infectious pathology. It continued after graduation and after specialization, initially at the same institution, subsequently at the UO Pediatria 1 Clinic of the University of Milan, called UO Pediatria at High Intensity of Care on August 19, 2013, then at the Pediatric Clinic of the University of Perugia and, therefore, at the Pietro Barilla Children's Hospital of the University Hospital of Parma on various topics of prevention, diagnosis and treatment of pediatric internal diseases.

The main contributions concerned:

1. Vaccines

• Immune response years after primary vaccination cycles
• Assessment of the immunogenicity, efficacy, safety and cost-benefit ratio of influenza vaccination in children
• Assessment of the immunogenicity, efficacy, safety and cost-benefit ratio of pneumococcal vaccines in children
• Evaluation of the immunogenicity, efficacy, safety and cost-benefit ratio of meningococcal vaccines in children
• Impact of different methods of preventing whooping cough in children
• Epidemiology of human papillomavirus (HPV) infections and study of the immunogenicity and safety of HPV vaccination in adolescents
• Immunogenicity and safety of vaccinations in immunocompromised children
• Immunogenicity and safety of vaccinations in children with rare diseases
• Safety, tolerability and efficacy of vaccinations in children with chronic diseases
• Immunogenicity and side effects of vaccinations in preterm infants
• Vaccinations during pregnancy for the protection of newborns and infants
• Development of a vaccine against respiratory syncytial virus

2. Infectious Diseases

- Influenza, SARS-CoV-2, respiratory syncytial virus and other respiratory viruses

• Clinical and socio-economic importance of influenza virus infections, respiratory syncytial virus infections and respiratory virus infections in general in different paediatric age groups
• Study of host genetic susceptibility to complications of influenza, rhinovirus infection and respiratory syncytial virus infection
• Clinical and socio-economic impact of SARS-CoV-2 infection in children
• Complications of SARS-CoV-2 infection in newborns, children and adolescents
• Prevention of SARS-CoV-2 infection
• Phylogenetic analysis of circulating respiratory viruses
• Development of monoclonal antibodies against respiratory syncytial virus

- Infections with invasive bacteria

• Epidemiology, diagnosis, clinical manifestations and therapy of invasive pneumococcal infections
• Epidemiology, diagnosis, clinical manifestations and therapy of invasive meningococcal infections

- Central nervous system infections

• Antibiotic therapy in bacterial meningitis
• Antiviral therapy in encephalitis
• Use of corticosteroids in bacterial meningitis and encephalitis

- Tuberculosis

• Epidemiology of tuberculosis in children and creation of the Italian Register of tuberculosis in pediatrics
• Sensitivity and specificity of new diagnostic methods in children
• Treatment of multidrug-resistant tuberculosis in children

- Respiratory and intestinal microbiome

• Impact of the respiratory and intestinal microbiome on infectious diseases
• Role of the respiratory and intestinal microbiome in respiratory diseases
• Role of the intestinal microbiome in neurological and psychiatric diseases

- HIV infection

• Vertical transmission of the infection
• Natural history of infection in children
• Antiretroviral therapy
• Prophylaxis of opportunistic infections
• Management of the social-welfare problems of the children of HIV-positive women

- Immunocompromised host infections other than HIV

• Epidemiology, diagnosis, clinical manifestations and therapy in the oncohematological child and in the transplanted child

- Rare and emerging infections

• Lyme disease in children
• Prevention and treatment of infections in the traveling child
• Prevention and therapy of nosocomial infections in pediatrics

- Anti-infectious therapy

• Pharmacokinetic studies of new antiinfectives in neonatal sepsis Antimicrobial approach aimed at serious infections in neonatal intensive care
• Surveillance of the use of antibiotics for the treatment of infectious diseases in wards and pediatric clinics
• Empirical anti-infective approach of choice in pediatric ICU
• Prophylaxis and perioperative therapy in the newborn and operated child
• Pharmacokinetics and pharmacodynamics of new antibiotics and antivirals

3. Pneumology

- Community pneumonia

• Etiology, diagnosis and therapy of community-acquired pneumonia
• Impact of new respiratory viruses (metapneumovirus, coronavirus, bocavirus, rhinovirus, enterovirus) in children with community pneumonia
• Role of Streptococcus pneumoniae in bacteraemic pneumonia
• Role of Mycoplasma pneumoniae and emergence of antibiotic resistant strains in the child with community pneumonia
• Therapeutic plans to be used in community-acquired pneumonia based on emerging pathogens and new antibiotic resistance issues
• Follow-up of children with severe pneumonia and analysis of risk factors for the development of bronchiectasis

- Bronchiolitis

• Role of the respiratory syncytial virus in affecting the remodeling of the airways in the newborn and infant with bronchiolitis
• Impact of new respiratory viruses (metapneumovirus, coronavirus, bocavirus, rhinovirus, enterovirus) in the infant with bronchiolitis
• Development of Italian guidelines on the management of bronchiolitis

- Bronchial asthma

• Etiology, diagnosis and therapy of bronchial asthma
• Genetic and epigenetic susceptibility in the child with bronchial asthma
• Role of macrolides in the therapeutic approach to the child with bronchial asthma
• Role of monoclonal antibodies in the treatment of severe bronchial asthma

-Cystic fibrosis

• Role of different pathogens in respiratory exacerbations
• Study of resistance to viruses and bacteria anti-infectives
• New CFTR protein modulators for personalised therapy
• Impact of telemedicine on clinical management and treatment adherence

4. Emergency-urgency

• High-flow oxygen therapy and non-invasive ventilation
• Acute and chronic pain therapy
• Use of antibiotic therapy in the Emergency Department and Intensive Care Unit
• Use of ultrasound in the Emergency Department

5. Nutrition

• Children without underlying conditions
• Role of vitamin D in the prevention of respiratory diseases
• Impact of micronutrients on the immune response
• Prevention and management of obesity
• Children with chronic diseases
• Role of nutrition in patients with cystic fibrosis
• Nutritional approach to patients with cancer
• Nutritional support in children with chronic gastrointestinal diseases

6. Allergy

- Respiratory allergy

• Impact of vaccines and immunostimulants in the prevention of respiratory allergy

- Allergy to drugs

• Study of allergy to antibiotics
• Study of allergy to antipyretics

- Skin allergy

• Study of risk factors for the development of atopic dermatitis
• Role of viral agents in urticaria

7. Immunology

- Immunogenetics

• Impact of polymorphisms of toll-like receptors in the immune response of the preterm infant
• Role of innate immunity in susceptibility to infectious diseases in children

- Primary and secondary immunodeficiencies

• Development of neonatal screening tests for the early identification of primary immunodeficiencies
• Prevention of infections in pediatric patients with primary or secondary immunodeficiencies 

8. Endocrinology and diabetology

-Endocrinology

• Early and late puberty
• Hypogonadotropic and hypergonadotropic hypogonadisms
• Congenital and acquired hypothyroidism, hyperthyroidism
• Short stature and GH deficiency
• Turner syndrome, Noonan syndrome, Klinefelter syndrome

- Diabetology

• Type 1 diabetes mellitus
• Type 2 diabetes mellitus
• Occasional hyperglycaemia

9. Rheumatology

Immune-mediated complications of Streptococcus pyogenes infections

• Kawasaki disease
• Role of infectious agents in juvenile idiopathic arthritis
• Role of infectious agents in systemic lupus erythematosus
• Role of infectious agents in hemophagocytic syndrome
• Immunogenicity and safety of vaccinations in patients with autoimmune diseases
• Therapy with biological drugs and infectious risk

10. Rare diseases

- Epidermolysis bullosa

• Multidisciplinary approach to the child with epidermolysis bullosa
• Hematological and nutritional aspects in the child with epidermolysis bullosa
• Innovative therapies in skin lesions that do not respond to standard treatment

- Rubinstein-Taybi syndrome

• Genotype-phenotype correlations in the child with Rubinstein-Taybi syndrome

- Neurofibromatosis

• New clinical manifestations of neurofibromatosis in children
• Child-adult transition in the patient with neurofibromatosis

- Metabolic diseases

• Unusual clinical presentations in children
• Safety and immunogenicity of vaccinations in relation to the type of metabolic disease

- Other rare diseases

• Identification of new genes associated with mental retardation
• Gene study of epileptogenic encephalopathies 

11. Otolaryngology

• Etiology, diagnosis and therapy of acute pharyngotonsillitis
• Possibility of short therapies with oral cephalosporins in streptococcal pharyngotonsillitis
• Etiology, diagnosis and treatment of acute otitis media
• Prevention of recurrent respiratory infections

The following were coordinated:

1. studies on the efficacy, safety and tolerability of vaccinations;

2. epidemiological research on the role of viruses and bacteria in the main infections of the pediatric age;

3. controlled clinical trials on the optimal schemes for the treatment of infectious diseases, pneumological diseases, allergic diseases and type 1 diabetes in children.

Furthermore, the following research periods have been spent at foreign research facilities:

• March 2007 -> Southwestern Medical Center, University Hospital and Clinic, Dallas, TX, USA;
• February 2009 -> St George's Medical Center, London, UK;
• July 2010 -> Kiremba Hospital, Kiremba, Burundi, Africa.

The main international collaborations concern research activities in pediatric infectious disease, pneumology and immunology and involve the Children's Hospital of Dallas (TX, USA), the Health Protection Agency of London (UK), the Erasmus MC of Rotterdam (The Netherlands), the Division of Clinical Virology of the University of Groningen (The Netherlands), St George's Hospital Medical School in London (UK) and the University of Oxford (UK).

From 1 September 1997 to 11 December 2000 she was the head of the research laboratory of the Pediatric Clinic IV of the University of Milan; from 12 December 2000 to 27 December 2016 she was the head of the research laboratory of the UO Pediatria 1 Clinic of the University of Milan, called UO Pediatria High Intensity of Care since 19 August 2013. The two laboratories under her guidance in the main Italian multicenter studies have become the reference for:

1. serological and molecular biology assays for the research of Mycoplasma pneumoniae and Streptococcus pneumoniae;

2. identification of common respiratory viruses (respiratory syncytial virus, influenza viruses, adenoviruses, parainfluenza viruses, rhinoviruses) and emerging (metapneumovirus, coronavirus, bocavirus, enterovirus);

3. evaluation of humoral and cell-mediated immune response to combined vaccines;

4. studies on the genetics of the host in response to different types of infection.

In 2012, Prof. Esposito identified two new Enteroviruses: enterovirus C-117 and enterovirus C-118 (http://www.picornastudygroup.com/types/enterovirus/ev_types.htm).

From 1 January 2017 to 31 August 2019, at the Santa Maria della Misericordia Hospital of the University of Perugia, she directed the following laboratories:

• Molecular Genetics Laboratory (Regional Reference Laboratory for the Diagnosis of Cystic Fibrosis);
• Postnatal Cytogenetics Laboratory.

In addition, in October 2016 the Clinical Trial Unit directed by Prof. Esposito at the IRCCS Ca 'Granda Hospital Maggiore Policlinico Foundation, University of Milan, Milan, and in September 2017 the Clinical Trial Unit directed by Prof.ssa Esposito at the Santa Maria della Misericordia Hospital, University of Perugia, Perugia, have received accreditation from AIFA for conducting phase 1 clinical studies in pediatric age.

Since 1 October 2020, he has coordinated the Paediatric Clinical Research Laboratory at the University of Parma.

On 10 June 2025, the intellectual property rights relating to digital content for online cognitive behavioural therapy (no. 152570) were registered with i-DEPOT.

Summary of the published works

The research activity resulted in 1248 publications in extenso in international journals with an overall impact factor (I.F.) of 6000 (Journal Citation Reports referring to the year of publication).

• Average Impact Factor> 4 for international publications.
• h index of 113 (Google Scholar), 92 (Scopus).
• Number of citations equal to 59,739(Google Scholar), 43,134 (Scopus).

Prof.ssa Esposito is in rank 76 of the Top Italian Scientists for Clinical Sciences:

http://topitalianscientists.org/TIS_HTML/Top_Italian_Scientists_Clinical_Sciences.html

In addition, we highlight:

• Articles in nationally distributed periodicals 613
• Nationally distributed volumes 15
• International circulation volume 3
• Chapters on international circulation volumes 21
• Chapters on national circulation volumes 39
• Disclosure articles 5510
• 1,946 invitations to invitations to congresses of Scientific Societies of which 960 invited invitations to congresses of International Scientific Societies and 986 invited invitations to congresses of National Scientific Societies

Knowledge and experience in clinical trials

Master's degree or advanced courses

• In the 2018-2019 academic year, she was the proponent and coordinator of the Advanced Course in Pre-clinical and Clinical Research at the University of Perugia;
• Since the 2020-2021 academic year, she has been the chair of the Level II Master's Degree in Pre-clinical and Clinical Research at the University of Parma;
• Since the 2021-2022 academic year, she has been the chair of the Level I Master's Degree in Artificial Intelligence and Telemedicine at the University of Parma;
• Since the 2021-2022 academic year, he is the president of the Level I Master's Degree in Scientific Communication at the University of Parma.
• Since the 2024-2025 academic year, he is the president of the Level I Master's Degree in Neonatal and Paediatric Ultrasound at the University of Parma

Experience in bioethics

• Member of the Interdepartmental Centre for Bioethics at the University of Parma (since February 2020), with the role of head of the Post-Pandemic Unit since February 2023;
• E-learning training course on “Ethics and Legality” at the University of Parma (January 2023);
• E-learning training course on “Healthcare and Social Assistance” at the University Hospital of Parma (15 March 2023);
• Course organised by the National Coordination Centre for Ethics Committees on Methods and Procedures for the Evaluation of Clinical Studies (February 2024);
• Course organised by the National Coordination Centre for Ethics Committees on Possible Evaluation Difficulties Associated with New Clinical Trial Designs (May 2024).

Master's degrees or training courses on personal data protection (privacy) legislation

• E-learning training course “Basic course on the corruption prevention system in public administration” Emilia-Romagna Region/SELF (May 26, 2020);
• E-learning training course “Training on privacy and data security” - University of Parma (July 7, 2020);
• E-learning training course “Transparency in Public Administration - Ed.01” University of Parma/Emilia-Romagna Region/SELF (November 15, 2021);
• E-learning training course “Basic course in IT security, 2021 edition, e-learning” University of Parma (December 13, 2021);
• E-learning training course “Privacy protection in healthcare” Coordination Privacy Group, Parma University Hospital (February 3, 2023);
• In-person ECM training course “How to survive privacy: updates for delegates in the healthcare sector” organized by the Parma University Hospital for Delegates for the processing of personal data (March 30, 2023).
• Training course “Obligation to report criminal conduct, personal data at the center, ethics and legality. The latest developments in whistleblowing and pantouflage” at the University of Parma (September 2025).

Teaching activity

Didactic activity carried out in the context of the teaching of General and Specialized Pediatrics of the Faculty of Medicine of the University of Milan:

• from the academic year 1999-2000 to the academic year 2016-2017 she also collaborated in practical exercises and guides students in setting up and discussing their theses by participating in the graduation sessions as co-supervisor;
• from the academic year 2000-2001 to the academic year 2016-2017, in addition to the assignments listed above, she carried out lessons and tutorial activities (exercises, seminars, discussion of clinical cases), being part of the commissions for the profit exams and participating at graduation sessions as co-supervisor;
• from 10 December 2002 to 30 September 2005 she carried out all the above assignments as University Researcher of General and Specialistic Pediatrics (scientific / disciplinary sector MED / 38) of the Faculty of Medicine and Surgery of the University of Milan (related at the Institute of Pediatrics);
• from the academic year 2003-2004 to the academic year 2016-2017 she was President of the Elective Course "Antibiotic Therapy in Pediatrics" of the Faculty of Medicine and Surgery of the University of Milan (duration: 40 hours, equal to CFU 2 );
• from 1 October 2005 to the 2016-2017 academic year shehas carried out all the above assignments as Associate Professor of General and Specialized Pediatrics (scientific / disciplinary sector MED / 38) of the Faculty of Medicine and Surgery of the University of Milan, participating in graduation sessions as a supervisor and co-supervisor;
• from the academic year 2006-2007 to the academic year 2016-2017 she was President of the Elective Course "Emergencies in Pediatrics" of the Faculty of Medicine and Surgery of the University of Milan (duration: 40 hours, equal to CFU 2) ;
• from the academic year 2007-2008 to the academic year 2010-2011 she was the President of the teaching course of General and Specialist Pediatrics (scientific / disciplinary sector MED / 38) at the Central Pole - Line H of the Faculty of Medicine and Surgery of the University of Milan and was the chairman of the examining commission of the related profit exams, also holding lessons for the courses of the Central Pole and the San Donato Pole;
• from the academic year 2011-2012 to the academic year 2016-2017 she was the President of the teaching course of General and Specialized Pediatrics in English (Pediatrics: scientific-disciplinary sector MED / 38) - Humanitas Line of the Faculty of Medicine and Surgery of the University of Milan and sheis the chairman of the jury for the related profit exams;
• in addition to the Pediatrics course, she continued to carry out lessons for the courses of the Central Pole and the San Donato Pole of the University of Milan and from 2010 to the 2016-2017 academic year she was supervisor of an average of 6 theses of degree for academic year. 

Didactic activity carried out within the School of Specialization in Pediatrics of the Faculty of Medicine of the University of Milan:

• in the academic year 2000-2001 she carried out tutorial activities;
• in the academic year 2001-2002 she was a contract professor, carrying out lectures and tutorial activities (exercises, seminars, discussion of clinical cases) and being part of the commissions for profit exams;
• from the academic year 2002-2003 to the academic year 2004-2005 she carried out lessons and tutorial activities (exercises, seminars, discussion of clinical cases), being part of the committees for the profit exams and participating in the specialization sessions as a co-supervisor in as University Researcher of General and Specialist Pediatrics (scientific / disciplinary sector MED / 38) of the Faculty of Medicine and Surgery of the University of Milan;
• from the academic year 2004-2005 to the academic year 2016-2017 she was responsible for the "Pediatric infectious diseases" course (duration: 6 hours, addressed to the first and second year of the school);
• from the academic year 2005-2006 to the academic year 2016-2017 she has carried out all the above assignments as Associate Professor of General and Specialistic Pediatrics (scientific-disciplinary sector MED / 38) by the Faculty of Medicine of the University of the Studies of Milan, participating in the specialization sessions as a speaker or co-supervisor;
• from the 2013-2014 academic year to the 2016-2017 academic year, she was the educational coordinator of the Polo (Central Pole) for pediatric specialists.

Teaching activity carried out within the Degree Course of Orthoptist and Ophthalmology Assistant of the University of Milan:

• from the academic year 2003-2004 to the academic year 2016-2017 she was the holder of the teaching of General and Specialized Pediatrics (scientific-disciplinary sector MED / 38) of the integrated course of interdisciplinary medical-specialist sciences (duration: 20 hours, equal to 2.5 CFU); it also guides students in setting up and discussing degree theses by participating in graduation sessions as co-supervisor.

Didactic activity carried out as part of the Degree Course in Nursing Pediatrician of the University of Milan:

• from the 2009-2010 academic year to the 2016-2017 academic year she was the teacher of Infectious Diseases in Pediatrics (duration: 10 hours).

Postgraduate courses of the University of Milan for which she was proposing and responsible:

• from the academic year 2011-2012 to the academic year 2016-2017 she carried out every two years as head of the specialization course in Emergency-urgency in developmental age at the University of Milan;
• from the 2012-2013 academic year to the 2016-2017 academic year, she carried out the two-year post-graduate course in Ultrasound in neonatal and pediatric age at the University of Milan as manager.

Didactic activity carried out at the University of Perugia:

• from the 2017-2018 academic year to the 2018-2019 academic year, she was the Director of the General and Specialistic Pediatrics Course of the School of Medicine of the University of Perugia, supervising more than 15 degree theses per year as supervisor academic;
• from the 2017-2018 academic year to the 2018-2019 academic year, she was the Director of the General and Specialized Pediatrics Course of the School of Dentistry of the University of Perugia;
• from May 2017 to August 2019 she was the contact person for the framework agreement of the University of Perugia-University of Chile;
• in the academic year 2017-2018, she was responsible for the visiting professors program of the University of Perugia of Prof. Miguel O'Ryan (Chile) and Federico Martinon Torres (Spain);
• from the 2017-2018 academic year to the 2018-2019 academic year, she was tutor vautatore for the internship in medicine for the state qualification exams to exercise the profession of Medical Surgeon University of Perugia.

Advanced courses at the University of Perugia:

• In the 2018-2019 academic year, she was the proponent and coordinator of the advanced course in pre-clinical and clinical research.
• Since the 2018-2019 academic year, she has been a lecturer on the Level II Master's Degree Course in “One Global Health Nutrition.”

Didactic activity carried out at the University of Parma:

• from the 2019-2020 academic year, she is the Director of the General and Specialized Pediatrics Course and of the Emergency Pediatrics Course of the School of Medicine and Surgery of the University of Parma;
• from the 2019-2020 academic year to the 2021-2022 academic year, she is the Director of the Course of Sports Pathology in Children in the Degree Course in Motor Sciences, Sport and Health of the University of Parma;
• from the 2019-2020 academic year to the 2021-2022 academic year, she is the Director of the Pediatrics Course in the Physiotherapy Degree Course of the University of Parma;
• from the 2019-2020 academic year to the 2021-2022 academic year, she is the Director of the Pediatrics Course in the Obstetrics Degree Course of the University of Parma;
• From the 2019-2020 to the 2021-2022 academic year, she was the Director of the Pediatrics Course in the Orthoptics Degree Program at the University of Parma;
• From the 2019-2020 to the 2021-2022 academic year, she was the Director of the Pediatrics Course in the Speech Therapy Degree Program at the University of Parma;
• From the 2019-2020 academic year, she has taught the elective course "General and Specialized Pediatrics" (equal to 1 credit) for fifth- and sixth-year students of the Medicine and Surgery Degree Program at the University of Parma;
• From the 2020-2021 to the 2003-2024 academic year, he taught the pediatric component of the elective course "Gender Medicine" (equal to 1 credit) for students in the fourth, fifth, and sixth years of the Degree in Medicine and Surgery at the University of Parma;
• From the 2022-2023 academi year to the 2023-2024 academic year, he taught the pediatric component of the elective course "Sustainability and Health" (equal to 1 credit) for students in the fourth, fifth, and sixth years of the Degree in Medicine and Surgery at the University of Parma;
• In the 2023-2024 academic year, he taught the pediatric component of the elective teaching activity "Vaccinations" (equal to 1 credit) for students in the fourth, fifth, and sixth years of the Degree in Medicine and Surgery at the University of Parma;
• Starting in the 2024-2025 academic year, he taught the elective teaching activity "Scientific Communication" (equal to 1 credit) for students in the third, fourth, fifth, and sixth years of the Degree in Medicine and Surgery at the University of Parma;
• Starting in the 2024-2025 academic year, he taught the elective teaching activity "Artificial Intelligence" (equal to 1 credit) for students in the third, fourth, fifth, and sixth years of the Degree in Medicine and Surgery at the University of Parma;
• starting from the 2024-2025 academic year, he/she will carry out the elective teaching activity “Telemedicine” (equal to 1 CFU) for students in the third, fourth, fifth and sixth years of the Degree Course in Medicine and Surgery at the University of Parma.

Didactic activity carried out at the Specialization School in Pediatrics of the University of Perugia:

• from December 28, 2016 to August 31, 2019, she was the Director of the School of Specialization in Pediatrics of the University of Perugia (n. Of specializing students: 30).

Teaching activities at the School of Specialization in Pediatrics at the University of Parma:

• Since February 12, 2020, he has been the Director of the School of Specialization in Pediatrics at the University of Parma (number of attending residents: 128).

Doctorate courses for which she has taught guiding:

• from the academic year 2010-2011 to the academic year 2012-2013 she followed the University of Milan's University of Milan as a lecturer in practice
• from the 2013-2014 academic year to the 2016-2017 academic year, she was part of the professors of the PhD program Epidemiology, Environment and Public Health;
• from the 2015-2016 academic year to the 2016-2017 academic year, she was a member of the Board of the PhD course Epidemiology, Environment and Public Health;
• from the 2017-2018 academic year, she is one of the teachers of the Doctorate Biology of Systems in Immune and Infectious Pathologies of the University of Perugia.
• In the 2020-2021 academic year, he was a member of the faculty of the Doctorate in Immunology, Molecular Medicine, and Biotechnology at the University of Rome Tor Vergata;
• Since the 2021-2022 academic year, he has been a member of the Faculty Board of the Doctorate in Translational Medical and Surgical Sciences at the University of Parma.

Master's and Advanced Courses at the University of Parma:

• Since the 2020-2021 academic year, she has been the president of the II-level Master's Program in Preclinical and Clinical Research;
• Since the 2021-2022 academic year, she has been the president of the I-level Master's Program in Scientific Communication;
• Since the 2021-2022 academic year, she has been the president of the I-level Master's Program in Artificial Intelligence and Telemedicine;
• Since the 2024-2025 academic year, she has been the president of the I-level Master's Program in Neonatal and Pediatric Ultrasound;
• From the 2020-2021 to the 2022-2023 academic year, she was the coordinator of the Professional Training and Refresher Course "Hospital School, Home Education, and Support Teachers";
• In the 2022-2023 academic year, she was a lecturer in the Master's Program in Thermal Treatments at the University of Parma.

Other Master's and Advanced Courses in which she participates:

• Since the 2023-2024 academic year, she has been a lecturer in the Master's Program in Pediatric Infectious Diseases at the University of Palermo;
• Since the 2023-2024 academic year, she has been invited to be a lecturer in the Master's Program in Infectious Diseases at the University of Turin;
• Since the 2023-2024 academic year, she has been invited to be a lecturer in the Master's Program in Pulmonology and Allergology at the Vanvitelli University of Naples;
• In the 2023-2024 academic year, she has been invited to be a lecturer in the Master's Program in Clinical and Functional Nutrition at the University of Chieti.

Other Specialization Schools for which she has carried out and is a guide teacher:

• from the academic year 2010-2011 to the academic year 2016-2017, she coordinated the clinical activity in pediatrics at the School of Specialization in Genetics of the University of Milan;
• from the 2015-2016 academic year to the 2016-2017 academic year, she was part of the teaching staff of the School of Specialization in Pediatric Surgery of the University of Milan;
• from the 2015-2016 academic year to the 2016-2017 academic year, she was part of the teaching staff of the Specialization School in Thoracic Surgery of the University of Milan from the 2015-2016 academic year to the 2016-2017 academic year , was part of the teaching staff of the School of Specialization in Thoracic Surgery of the University of Milan;
• in the 2018-2019 academic year, she was part of the teaching staff of the School of Specialization in Obstetrics and Gynecology of the University of Perugia.
• Since the 2019-2020 academic year, he has been a member of the faculty of the School of Specialization in Obstetrics and Gynecology at the University of Parma;
• Since the 2019-2020 academic year, he has been a member of the faculty of the School of Specialization in Orthopedics and Traumatology at the University of Parma;
• Since the 2019-2020 academic year, he has been a member of the faculty of the School of Specialization in Physical Rehabilitation Medicine at the University of Parma;
• Since the 2019-2020 academic year, he has been a member of the faculty of the School of Specialization in Diagnostic Radiology at the University of Parma;
• Since the 2019-2020 academic year, he has been a member of the faculty of the School of Specialization in Pediatric Dentistry at the University of Parma.

Didactic activity carried out in foreign universities:

• from the academic year 2009-2010 (continues to this day), she participates as a teacher in the Pediatric Infectious Diseases Diploma of the University of Oxford, UK;
• in November 2019, she lectured as an invited professor at Sechenov University in Moscow;
• from the academic year 2009-2010 to the academic year 2012-2013, she participated as invited professor in the refresher lessons in pediatric infectious disease at St George's University in London, UK;
• in March 2007, as invited professor, lectured at the Pediatric Infectious Diseases Division of the Southwestern Medical Center, University Hospital and Clinic, in Dallas, TX, USA;
• in February 2008, as invited professor, she participated in a round table on nosocomial infections at the University Hospital of Geneva (Geneva, Switzerland);
• in October 2014, she served on the PhD Commission at the University of Groningen (Groningen, the Netherlands);
• in July 2016, as invited professor, she did teaching in pediatric infectious disease for the University of Turku in Finland.
• in November 2019, as an invited professor, he carried out teaching activities in pediatric infectious diseases for the Sechenov University of Moscow (Moscow, Russia);
• in May 2024, as an invited professor, he was part of the Commission for the Evaluation of Associate Professors of Pediatrics of the University Medical School of Cyprus, Cyprus.

Other didactic activities:

• from the academic year 1997-1998 she was invited to frequently give reports and lessons on pediatric and infectious disease topics at the main National and International Congresses of Pediatrics and Infectious Diseases;
• since the academic year 1997-1998 she has taught Antibiotic Therapy and Infectious Disease Courses as part of the training programs of the Italian Society of Pediatrics;
• since the academic year 1999-2000 she has held reports and seminars within the Theoretical-Practical Courses of Pediatric Otolaryngology organized by the Italian Society of Pediatric Infectivology;
• in the academic year 1999-2000 she participated in the teaching activity of the School of Specialization in Infectious Diseases of the Faculty of Medicine and Surgery of the University of Milan;
• in the academic year 1999-2000 she participated in the teaching activity in the Postgraduate Course in "Emerging and Re-emerging Pediatric Infectious Diseases" of the University of Florence;
• in the academic year 2003-2004 she carried out as an instructor the training courses on SARS of the Lombardy Region at the Clinical Institutes of Improvement;
• from the academic year 2006-2007 to the academic year 2009-2010 she was a teacher at the integrated course C1 (integrated course of systems of IT applications for applied medical teaching) of the Master's degree in distance learning in medicine;
• since September 2016, she has been carrying out emergency-urgency training activities as head of the SIMEUP Milan Pediatrics Emergency Center (EMiPed);
• in October 2016, she worked as a Mentor for specialists interested in pediatric infectious disease for the Infectious Disease Society of America (IDSA) in New Orleans (LO, USA).
• In October 2020, she was appointed as a lecturer by the Regional Observatory of Specialty Schools of Emilia-Romagna on the role of pediatrics (The role of children and adolescents) in the COVID-19 emergency as part of the training program for residents of the four universities in the region on the topic: Management of Emergencies, Epidemics, and Catastrophes (GEEC).
• In the 2021-2022 academic year, she conducted pediatrics research in the RER ALFONSA Project (Higher Education and Innovation for the Sustainable Development of the Apennines).

Assistance activity

• Trainee at the Pediatric IV Clinic of the University of Milan: from November 1, 1995 to October 31, 1999.
• Internal university doctor at the Pediatric Clinic IV of the University of Milan: from November 1, 1999 to March 12, 2000.
• 1st level alternate medical director at the IV Pediatric Clinic of the L. Sacco Hospital in Milan: from 13 March 2000 to 12 November 2000.
• 1st level medical officer in charge at the IV Pediatric Clinic of the L. Sacco Hospital in Milan: from 13 November 2000 to 11 December 2000.
• 1st level medical director in charge of the Pediatric Clinic I of the Clinical Institutes of Milan: from 12 December 2000 to 31 July 2001.
• 1st level medical director at the Pediatric Clinic I of the Clinical Institutes of Milan: from 1 August 2001 to 9 December 2002.
• University researcher with an agreement with the Pediatric Clinic I of the Clinical Institutes of Improvement in Milan: from 10 December 2002 to 31 January 2005.
• Head of the outpatient infectious disease service and consultancy in infectious disease at the Pediatric Clinic I of the Clinical Institutes of Improvement in Milan: from 10 December 2002 to 31 January 2005.
• University researcher with an agreement with the UOC Pediatrics 1 Clinic of the IRCCS Ca 'Granda Maggiore Policlinico Hospital, Milan: from 1 February 2005 to 30 September 2005.
• Head of the Reference Center for Pediatric AIDS of the Lombardy Region at the UOC Pediatrics 1 Clinic of the IRCCS Ca 'Granda Ospedale Maggiore Policlinico Foundation, Milan: from 1 February 2005 to 27 December 2016.
• Head of the Pediatric AIDS Reference Center for the Lombardy Region at the Pediatrics 1 Clinic of the IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, Milan: from February 1, 2005 to December 27, 2016.
• Head of the outpatient infectious disease and immunoprophylaxis service and consultancy in infectious disease at the UOC Pediatrics 1 Clinic of the IRCCS Ca 'Granda Hospital Maggiore Policlinico Foundation, Milan: from February 1, 2005 to December 27, 2016.
• Head of the Center for the traveling child at the UOC Pediatrics 1 Clinic of the IRCCS Ca 'Granda Maggiore Policlinico Hospital, Milan: from 1 May 2005 to 27 December 2016.
• Adjunct associate professor at the UOC Pediatrics 1 Clinic of the IRCCS Ca 'Granda Maggiore Policlinico Hospital, Milan: from 1 October 2005 to 27 December 2016.
• Head of the Pediatric Infectivology Simple Operative Unit at the UOC Pediatrics 1 Clinic of the IRCCS Ca 'Granda Maggiore Maggiore Policlinico Hospital, Milan: from December 19, 2007 to December 27, 2016.
• Deputy director of the Pediatrics 1 Clinic of the IRCCS Ca 'Granda Hospital Maggiore Policlinico Foundation, Milan: from 1 July 2006 to 29 November 2010.
• Head of the Regional Reference Center for Lyme disease in children: from 1st January 2011 to 27th December 2017.
• Head of the Multidisciplinary Center for epidermolysis bullosa at the IRCCS Ca 'Granda Maggiore Policlinico Hospital: from March 1, 2012 to December 27, 2016.
• Head of the SIMEUP Center for the execution of BLS, PBLS and PEARS: from September 1, 2016 to December 27, 2016 in Milan, from December 28, 2016 to August 31, 2019 in Perugia and from September 1, 2019 and still continues in Parma.
• Director of the Pediatrics Unit, Clinic 1 of the IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, Milan, renamed the High-Intensity Pediatrics Unit from August 19, 2013: from November 30, 2010 to August 18, 2012 as acting Director of the Complex Unit and from August 19, 2013 to December 27, 2016 as Director of the Departmental Unit;
• Director of the Pediatric Clinical Unit at the University of Perugia from January 1, 2017, to August 31, 2019;
• Director of the Umbria Regional Center for Pediatric Diabetes and member of the Inter-Company Diabetes Group at ASL 1 Umbria: from January 1, 2017, to August 31, 2019;
• Program assignment equivalent to a UOC for Hospital-Territory Integration at the Parma University Hospital: from September 1, 2019, to October 30, 2019;
• Director of the Pediatric Clinical Unit at the Pietro Barilla Children's Hospital at the Parma University Hospital: from November 1, 2019, and continuing.

Since July 2024, member (in three cases as Coordinator) of the following Working Groups identified by the National Guidelines Center of the Italian National Institute of Health (Istituto Superiore di Sanità)

• Member of the national intersociety Working Group for drafting Guidelines (LG) on reproductive health
• Member of the national intersociety Working Group for drafting Guidelines (LG) on endometriosis
• Member of the national intersociety Working Group for drafting RCBP on sepsis in pregnancy
• Member of the national intersociety Working Group for drafting RCBP on lower respiratory tract infections
• Member of the national intersociety Working Group for drafting RCBP: preoperative anesthesiology assessment of the pediatric patient
• Coordinator of the national intersociety Working Group on Telemedicine and digital innovation in the management of chronic pediatric respiratory diseases
• Member of the national intersociety Working Group for drafting RBPCA on vascular access in the pediatric patient
• Member of the national intersociety Working Group for drafting RBPCA for hospitalization of the pediatric patient with asthma
• Member of the national intersociety Working Group for drafting RBPCA on prevention of venous thromboembolism in pediatric fractures
• Member of the national intersociety Working Group for drafting RBPCA on the clinical management of Post-Traumatic Stress Disorders in pediatric patients (0–16 years)
• Member of the national intersociety Working Group for drafting Guidelines (LG) on obesity
• Coordinator of the national intersociety Working Group on diagnosis and treatment of tuberculosis in pediatric age
• Coordinator of the national intersociety Working Group on prescribing appropriateness in pediatric allergology
• Member of the national intersociety Working Group on psychological distress in adolescence

Participation in institutional and regional refresher courses in 2024

• Masterclass for evaluators: workshop on leadership styles (29/01)
• Assessment and classification of pressure injuries – 2024 edition (27/01)
• Course 1 – Prevention of infectious risk and antimicrobial resistance – 2024 edition (26/01)
  Course 2 – Prevention of Healthcare-Associated Infections (HAIs) – 2024 edition (26/01)
  Course 3 – Antimicrobial Stewardship – 2024 edition (30/01)
  Course 4 – Synergies and integration between risk management and infectious risk – 2024 edition (30/01)
• Difficult airway management – 2024 edition (31/01)
• Emergency Department triage: new colors for welcoming – 2024 edition (31/01)
• Course of the National Coordination Center of Ethics Committees (CCNCE) – AIFA on methods and procedures for the evaluation of clinical studies (08/02)
• Restraint (contenzione) – 2024 edition (15/02)
• Infectious disease courses: management of epidemic and pandemic events; sepsis prevention and control; vaccination and healthcare workers (18/03)
• Course of the CCNCE – AIFA on possible assessment difficulties associated with new clinical trial designs (06/04)
• Prevention and contrast of female genital mutilation (24/06)
• The father in the first 1,000 days of life (27/07)
• Reception and care of child victims of maltreatment/abuse: modules 1, 2 and 4 (15/12 and 17/12)

Managerial training course for Manager of Complex Structure (Code DSC1701) in 2017-2018 at PoliS Lombardia with discussion on May 15, 2018 of a project work entitled "Proposal of an inter-company Umbrian maternal-child network (RIUMI)" ( Guide teacher: Dr. L. Macchi; Tutor: Dr. A. Zoli).

Management training course for Director of Healthcare Structure carried out in 2019 at PoliS Lombardia with discussion on October 16, 2019 of a project work entitled "The relationship between Socio-Territorial Healthcare Companies (ASST) and Health Protection Agencies (ATS) in the path of reorganization of the offer network in accordance with Ministerial Decree (DM) 70/2015 "(Teacher guide: Dr. Marco Bosio).

Scientific responsibility for international and national research projects admitted to funding on the basis of competitive calls for peer review

At regional level, she was awarded as Principal Investigator for the following projects:

• Cassa di Risparmio di Perugia (2018) – Role of Aspergillus fumigatus in the respiratory pathology of children and adolescents with cystic fibrosis (duration: 24 months);
• A.R.C.O. Project – Umbria Region (2018) – The electronic health record in children (duration: 12 months);
• “Alte Competenze” Call – Emilia-Romagna Region (2019) – Impact of big data and artificial intelligence on precision medicine of respiratory infections in children (duration: 12 months);
• FSE+ Call (2nd edition) – Advanced Training Course DIGItal Technology and Telemedicine for healthCARE – DIGICARE (duration: 18 months) – €235,870.80 – ongoing.

She coordinated the pediatric work package in the following project:

• Lombardy Region (2011): “Evaluation and monitoring of HPV infection and related diseases in women at high risk for cervical cancer” (duration: 60 months).

Since 2020, at the University of Parma, she has annually been ranked within the top quartile of professors receiving FIL funding, based on scientific output.

At Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, she coordinated the following competitive project (2013–2014), for which she was awarded funding:

• Serum microRNAs as novel biomarkers of response to vaccination in healthy infants (duration: 24 months).

She also supervised the competitive project (2015–2016) awarded to Dr. Samantha Bosis, carried out at the High-Intensity Care Pediatric Unit:

• Genetic polymorphisms and susceptibility to invasive infections in the neonatal and pediatric age (duration: 24 months)

Internationally, she was responsible for workpackage in the following projects:

• DG Sanco project No. A / 101039 in the Second Program of Community Action in the Field of Health (2008-2013) - Antibiotic resistance and prescribing in European children (duration: 60 months);
• ERC (European Research Council) Advanced Grant 2009, proposal no. 250290 - The hygiene hypothesis: revisiting the concept by integrating epidemiology and mechanistic studies: case-control study "(duration: 48 months);

She was responsible for workpackage in the following projects:

• No. 242146 in FP7-HEALTH-2009 - European multicenter network to evaluate PK, safety and efficacy of meropenem in neonatal sepsis and meningitis (duration: 48 months);
• H2020-FTIPilot-2015-1- Fast tracking market adoption of a novel immune-based diagnostic for improving antibiotic stewardship: automation, piloting and health economics (AutoPilot-Dx; duration: 28 months).
• IMI-JU-2013 - Standardization and Development of Assays for Assessment of Influenza Vaccine Correlates of Protection (duration: 48 months).

At the national level, it participated in the MIUR project No. 2005068289_001 entitled "Influenza vaccination in children: vaccination coverage in children with chronic and healthy diseases and vaccine efficacy in the epidemic period" (duration: 36 months).

She was the scientific director of the following regional competitive tenders in Umbria:

- Role of Aspergillus fumigatus in the respiratory pathology of children and adolescents with cystic fibrosis funded by the Cassa di Risparmio di Perugia Foundation (duration: 12 months);

- Pediatric medical record within the electronic health record (duration: 12 months).

She also coordinated the following projects as principal investigator:

• RF Young Researchers Call 2007 (Ministry of Labor, Health and Social Policies) "Impact of influenza and immunogenicity and efficacy of influenza vaccination in children: clinical and socio-economic evaluation in hospital and in the territory" (duration: 48 months) ;
• Young Researchers RF 2009 Call (Ministry of Labor, Health and Social Policies) "Genetic variants and susceptibility to severe and / or recurrent lower respiratory tract infections with wheezing in children" (duration: 48 months).

Scientific responsibility as principal investigator in other research projects

• Multi-center, randomized, blinded, controlled study to evaluate the clinical efficacy against chickenpox of the live attenuated varicella vaccine against GlaxoSmithKline Biologicals (VarilrixTM) administered as a single dose and of the combined measles-mumps-rubella vaccine- chickenpox of GlaxoSmithKline Biologicals (Priorix - Tetra) administered in two doses to healthy children during the second year of life (OKAH179 & Ext) GlaxoSmithKline (GSK) Biologicals (2006-2016)
• Descriptive epidemiological study of community pneumonia in children in the first years of life hospitalized in Italy: comparison between two different methods of diagnosis (2010-2012)
• Evaluation and monitoring of HPV infection and related diseases in women at high risk for carcinoma of the uterine cervix Lombardy Region (2010-2014)
• Prospective open-label evaluation of the pharmacokinetics / pharmacodynamics and safety of oseltamivir (Tamiflu) in the treatment of infants from 0 to <12 months with confirmed influenza infection (2010-2012)
• Primary, multicenter, Phase IIIb, open label, randomized clinical trial, aimed at evaluating the immunogenicity and safety of the HPV - 16/18 L1 VLP AS04 vaccine of GlaxoSmithKline (GSK) Biologicals administered to healthy girls of 9 -14 (2010-2012)
• A phase III, randomized, observer - blind, controlled, multi - center clinical study to evaluate the efficacy, safety and immunogenicity of one and two intramuscular doses of FLUAD® versus control vaccines in unprimed healthy subjects aged 6 to 72 months (2010- 2011)
• A phase 2b, open label, randomized, parallel-group, multi-center, study to evaluate the safety, tolerability and immunogenicity of Novartis meningococcal B recombinant vaccine when administered with or without routine infant vaccinations to healthy infants according to different immunization schedules ( 2010-2012)
• A phase 2b, open label, multi-center, extension study to evaluate the safety, tolerability and immunogenicity of a booster dose of Novartis meningococcal B recombinant vaccine administered at 12, 18 or 24 months of age in subjects who previously received a three- dose primary series of the Novartis meningococcal B Recombinant Vaccine as Infants in study V72P12 (V72P12E1) (2011-2013)
• A phase 3, partially blinded, randomized, multi-center, controlled study to evaluate immunogenicity, safety and lot to lot consistency of Novartis meningococcal B recombinant vaccine when administered with routine infant vaccinations to healthy infants (V72P13) (2011-2013)
• A phase 3, open label, multi-center, extension study to evaluate the safety, tolerability and immunogenicity of a booster dose of Novartis meningococcal B recombinant vaccine when administered as a booster at 12 months of age or as a two-dose catch- up to healthy infants who participated in study V72P13 (V72P13E1) (2011-2013)
• A phase III randomized, open label, multicenter, parallel group clinical trial in children aged 6-36 months to compare the immunogenicity and safety of a single 0.5 ml dose of Inflexal V compared to two 0.25 mL doses of Inflexal V administered according to a 0/4 week dosing schedule (2011-2012)
• Phase 2 partially observer-blind randomized controlled multicenter dose-ranging and formulation-finding study to evaluate the safety and immunogenicity of a new recombinant type B Novartis meningococcal vaccine when administered concomitantly with routine vaccines to 2-month-old children age (2011-2013)
• Impact of respiratory viruses in cystic fibrosis patients hospitalized for respiratory exacerbations and role of vitamin D deficiency in conditioning the risk and severity of serious viral infections
• Monitoring of infections from influenza viruses and other respiratory viruses in children (2011-2012)
• Polymorphisms and susceptibility to severe and / or recurrent lower respiratory tract infections with bronchospasm in children (2011-2016)
• Impact of environmental pollution on a pediatric population with recurrent wheezing or bronchial asthma (2011-2012)
• Genetic polymorphisms and susceptibility to serious and / or recurrent lower airway infections with pediatric bronchospasm (2011-2012)
• Epidemiological study on the prevalence of Lyme disease in children (2011-2012)
• Study on the immunogenicity and safety of the live attenuated vaccine against measles, mumps, rubella, varicella of GlaxoSmithKline Biologicals (PriorixTetraTM) co-administered with the MenC conjugate vaccine (Meningitec, Wyeth Lederle) in healthy children (2011-2013)
• Open-label, phase 3 multicenter extension study to evaluate persistence and antibody response to a third or fifth dose of Novartis recombinant antimeningococcal B vaccine in 4-year-old children who have already participated in study V72P12E1 (2012-2014 )
• Impact of immunostimulant therapy on the immune response to influenza vaccination in children with a history of recurrent respiratory infections or recurrent otitis media (2012-2014)
• Immunogenicity, safety and tolerability of influenza vaccination in children and adolescents with metabolic diseases (2012-2014)
• Definition of new inflammatory markers of severity and etiology in the child with community pneumonia (CAP) and their correlation with the pulmonary ultrasound parameters (2012-2014)
• Study on the safety and efficacy of the combination of inhaled fluticasone propionate and inhaled salmeterol compared to inhaled fluticasone propionate in the treatment of adolescent and adult subjects with severe asthma (2012-2014)
• Prospective observational study on the immunogenicity and safety of HPV vaccination in adolescents with autoimmune diseases (2012-2013)
• Randomized, double-blind, randomized versus placebo study on the efficacy and tolerability of rhinogermin in the preventive therapy of acute otitis media in the pediatric population with a history of recurrent acute otitis media (2013-2014)
• Nutritional status of hospitalization and hospital malnutrition in children: association with the clinical course (2013-2014)
• Multi-center, randomized, double-blind comparative study to evaluate the efficacy, safety and pharmacokinetics of daptomycin compared to an active comparator in pediatric subjects with acute hematogenous osteomyelitis due to gram-positive organisms (2013-2017) 
• Comparative evaluation of the safety and efficacy of daptomycin compared to the standard of care in pediatric subjects of 2-17 years of age with bacteraemia caused by Staphylococcus aureus (2013-2016)
• Monitoring of influenza virus infections in children (2013-2014)
• Immunogenicity, safety and tolerability of influenza vaccination in children and adolescents with chronic renal failure (2013-2014)
• Clinical and immunomodulatory effects of antibiotic therapy associated with pidotimod versus the only antibiotic therapy in children with community-acquired pneumonia (CAP) (2013-2015)
• Assessment of pituitary function in children with infectious meningitis (2013-2014)
• Use of platelet gel in the treatment of ulcerative lesions in patients with hereditary epidermolysis bullosa: evaluation of the remedial efficacy versus the gold therapeutic standards on the market and on the prevention of spino-cellular carcinomas (2013-2015)
• Surveillance of respiratory syncytial virus (RSV) infection and disease in children younger than 2 years (2013-2014)
• Nasopharyngeal colonization by Streptococcus pneumoniae in healthy or high-risk children and adolescents, aged between 6 and 17 years (2013-2014)
• Clinical efficacy and safety of J0022X ST in the prevention of recurrent upper airway infections (2014-2016)
• Phase 2/3 open-label study to evaluate pharmacokinetics, safety and antiviral activity in a single tablet regimen (STR) of elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (E / C / F / TAF) in affected adolescent patients HIV-1 naïve to antiretroviral treatment (2014-2017)
• Phase 3 clinical trial, randomized, with active control, with blinded observer, to evaluate the lot correspondence, safety, tolerability and immunogenicity of rLP2086 vaccine for serogroup B meningococcus in healthy subjects aged ≥ 11 e <19 years (2014-2015)
• Open-label, randomized, multicenter, phase-defining Ib study to analyze the pharmacokinetics / pharmacodynamics of oseltamivir (tamiflu) in the treatment of influenza in immunocompromised children, aged 0 to 18 years, with confirmed infection of influence (2014-2018)
• Study on the efficacy and immunogenicity of the quadrivalent flu vaccine administered intramuscularly in healthy children aged between 6 and 35 months (2014-2018)
• Phase IIIb multicenter, controlled, open-label study to evaluate the safety, tolerability and immunogenicity of two doses of the Novartis group B meningococcal vaccine administered to immunocompromised patients between 2 and 17 years of age who present a higher risk to develop meningococcal disease due to a complement deficiency or asplenia, compared to a control group made up of healthy subjects (2014-2015)
• Study on the duration of protection from pneumococcal colonization induced by conjugate vaccines (2014-2015)
• Phase 3, multicenter, randomized, double-blind, placebo-controlled study on the efficacy and safety of SD-101 in cream in patients with epidermiolysis bullosa (2014-2018)
• Immunogenicity, safety and tolerability of the inactivated trivalent vaccine against influenza in obese children and adolescents (2014-2015)
• Phase III clinical trial, stratified, randomized, blinded to the observer, controlled, multicenter to evaluate the safety, immunogenicity and efficacy of an adjuvanted influenza virus vaccine with a quadrivalent subunit compared to an influenza vaccine non-adjuvanted comparison in children aged ≥ 6 and <72 months (2014-2015)
• Research of the autoimmune component in epidermolysis bullosa (RiCoA-EB) (2014-2016)
• Phase 3 multicenter, parallel group, randomized, blinded study for the investigator, to examine the safety and efficacy of the oral suspension or fidaxomycin tablets taken every 6 hours for 10 days in pediatric subjects with diarrhea associated with Clostridium difficult (2014-2017)
• Etiological role of viruses and bacteria in the child with acute respiratory failure (IRA) hospitalized in Pediatric Intensive Care (2014-2016)
• Double-blind, randomized, stratified, multi-center trial for the evaluation of oseltamivir in a conventional and double dose in the treatment of influenza in immunocompromised patients (2014-2018)
• Chronic cough as an indicator of Bordetella pertussis infection and as an indication of lack of vaccination coverage (2014-2017)
• Surveillance for respiratory syncytial virus (RSV) infection and disease in elderly aged> 65 years (2014-2015)
• Open-label multicenter study to evaluate the safety, tolerability, pharmacokinetics and efficacy of ceftaroline in infants and young children with late-onset sepsis (2015-2017)
• Open-label, multicenter extension study aimed at assessing the long-term safety of Zorblisa ™ (SD-101-6.0) in patients with epidermolysis bullosa (2015-2018)
• Epidemiological study of the etiology of acute otitis media complicated by spontaneous perforation in children (2015-2016)
• Influence of different sources of information on the acceptance of vaccinations in adolescents (2015-2016)
• Randomized, double-blind clinical trial on the efficacy and tolerability of intranasal administration of rhinogermine in the prevention of acute otitis media in children with a history of recurrent acute otitis media (2015-2017)
• Study of the family burden in patients with epidermolysis bullosa (2016-2018)
• Evaluation of the persistence of nasopharyngeal colonization with Streptococcus salivarius 24SMB and Streptococcus oralis 89a after their administration with nasal spray for 5 and 7 days (2016-2017)
• Nasopharyngeal colonization by Staphylococcus aureus in children and adolescents undergoing surgery (2015-2017)
• Clinical and functional characteristics of obese pediatric patients with bronchial asthma (2016-2017)
• Randomized, double-blind, placebo-controlled prospective study to evaluate the number, duration and severity of upper respiratory tract infections in children at high risk of recurrence after standard treatment with the bacterial lysate "Paspat 3 mg tablets" in the span of a six-month observation period (2016-2017)
• Phase I / II multicenter clinical trial, randomized and controlled, with blinded observer, at increasing dosages, aimed at assessing the safety, reactogenicity and immunogenicity of the experimental vaccine (GSK3389245A) of GlaxoSmithKline Biologicals directed against the respiratory syncytial virus (RSV) and based on viral proteins F, N and M2-1 encoded by the adeno-carrier ChAd155-RSV, when administered intramuscularly, according to a schedule at 0, 1-months, to RSV-seropositive children aged between 12 and 17 months (2016-2017)
• Phase IV, randomized, controlled, double-blind pharmacological study on the efficacy and safety of OM-85 in children with recurrent respiratory infections (2016)
• Phase 3 study, randomization, blinded for the observer, controlled by placebo, sequential in groups for the determination of the immunogenicity and safety of a recombinant nanoparticle vaccine against respiratory syncytial virus (RSV) F with aluminum in women in the third trimester of pregnancy, and RSV disease in the newborn (2016)
• A phase 1b randomized, partially double-blind, placebo-controlled study to evaluate the pharmacokinetics, safety and tolerability of multiple doses of JNJ-53718678 administered orally in hospitalized children with VRS infection (2016)
• Phase IV, blinded, randomized, cross-over, placebo-controlled, multicenter study to evaluate the immunogenicity and safety of a single dose of Boostrix ™ in pregnant women (2016)
• Open-label, non-randomized multicenter phase IV study to evaluate the immunogenicity and safety of Infanrix hexa® when administered as primary vaccination in infants born healthy to mothers vaccinated with Boostrix® during pregnancy or postpartum in study 116945 [ DTPA (BOOSTRIX) -047] (2016-2018)
• AUTOPILOT-DX: Pilot study, multicenter, prospective, to validate the diagnostic accuracy and evaluate the potential clinical utility of a diagnostic tool based on the host's response to distinguish between bacterial and viral etiologies in pediatric patients who come to the emergency room with respiratory tract infections (RTI) and fever of unknown origin (FWS) (2017).
• INFQ3003: Phase III study, blinded for the observer, randomized, controlled with a non-flu vaccine by comparison, parallel groups, multinational conducted on children aged between 6 and 35 months to evaluate the safety and efficacy of the Abbott candidate quadrivalent flu vaccine (2017)
• EPID-ASTHMA: Epidemiology of bronchial asthma in adolescence (2017)
• MAGICAL: Impact of continuous blood sugar control on metabolic control and quality of life in patients with diabetes of pediatric age in multi-injection therapy (2018)
• Multicenter observational study on the management and follow-up of febrile seizures in the pediatric population belonging to the DEA of the AOY Meyer in Florence and the pediatric clinic of the AOU of Perugia (2017).
• Diagnostic value of presepsin in infants less than 3 months of age with fever without origin (2017)
• With your legs and your heart, beyond diabetes (2017)
• Respiratory microbiota in children with recurrent acute otitis media (2017)
• Immunogenicity, safety and tolerability of a quadrivalent vaccine for influenza +/- probiotics in children with type I diabetes (2017 )
• BPA-PUBERTY: Observational study on the role of Bisphenol A and phthalates in early puberty (2017)
• BIOMARK-ASTHMA: Biomarkers for a possible development of asthma in Umbrian children suffering from allergic rhinitis (2017)
• SIBO-INFL: Correlation between intestinal bacterial proliferation (SIBO) and low-grade systemic inflammation in obese children (2018)
• PED-17-05: Prospective assessment on the acceptance of vaccinations following the approval of the decree law on the vaccination obligation in children and adolescents in the Umbria region (2018-2019)
• HZA107116: Randomized, double-blind, parallel group, multicenter, stratified study to evaluate the efficacy and safety of inhaled powder of fluticasone furoate / vilanterol administered once daily compared to inhaled powder of fluticasone furoate administered once. once a day in the treatment of asthma in participants aged 5 to 17 years who are currently not controlled with inhaled corticosteroids (2018).
• RSVPED-002: Phase I / II multicenter clinical trial, randomized and controlled, with blinded observer, at increasing dosages, aimed at assessing the safety, reactogenicity and immunogenicity of the experimental vaccine (GSK3389245A) of GlaxoSmithKline Biologicals directed against the respiratory syncytial virus (RSV) is based on the viral proteins F, N and M2-1 encoded by the adeno-carrier ChAd155-RSV, when administered intramuscularly, according to a schedule at 0, 1-months, to RSV-HIV-positive children aged between 12 and 23 months (2018).
• A multi-center, Phase I, open-label study to investigate pharmacokinetics (PK) of ticagrelor in infants and toddlers, aged 0 to 24 months, with sickle cell disease (2018).
• DATABASE-CELIACHIA: Database for the collection of information on the methods of diagnosis of celiac disease in children and adults following the dissemination of the update of the guidelines for the diagnosis of celiac disease by the European Society of Pediatric Gastroenterology ( 2018).
• HZA107116: Randomized, double-blind, parallel group, multicenter, stratified study to evaluate the efficacy and safety of the inhaled powder of fluticasone furoate / vilanterol administered once daily compared to the inhaled powder of fluticasone furoate administered once. once a day in the treatment of asthma in participants aged 5 to 17 years who are currently uncontrolled with inhaled corticosteroids (2018).
• RSVPED-002: Phase I / II multicenter clinical trial, randomized and controlled, with blinded observer, at increasing dosages, aimed at assessing the safety, reactogenicity and immunogenicity of the experimental vaccine (GSK3389245A) of GlaxoSmithKline Biologicals directed against the respiratory syncytial virus (RSV) is based on the viral proteins F, N and M2-1 encoded by the adeno-carrier ChAd155-RSV, when administered intramuscularly, according to a schedule at 0, 1-months, to RSV-HIV-positive children aged between 12 and 23 months (2017).
• HESTIA4: A multi-center, Phase I, open-label study to investigate pharmacokinetics (PK) of ticagrelor in infants and toddlers, aged 0 to 24 months, with sickle cell disease (2018).
• 63623872FLZ3001: A Phase 3 Randomized, doubleblind, placebocontrolled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ63623872 in Combination With Standard of care Treatment in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection (2018).
• 63623872FLZ3002: A phase 3 randomized, doubleblind, placebocontrolled, multicenter study to evaluate the efficacy and safety of jnj63623872 in combination with standardofcare treatment in adolescent, adult, and elderly nonhospitalized patients with influenza a infection who are at risk of developing complications (2018).
• V114-023: A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children with Sickle Cell Disease (PNEU – SICKLE) (2018) .
• MET58: Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe (2018).
• LONG COVID: Consequences of COVID-19 infection on the health and well-being of children and adolescents (2021).
• MED4Youth: Mediterranean Enriched Diet for tackling Youth Obesity (2021).
• PRESO: Early use of substances (tobacco, alcohol and cannabis) in preadolescents accessing hospital pediatric services (2022).
• RESPIRIAMO: Italian Hospital Surveillance for Lower Respiratory Tract Infections (2022).
• AEZS-130-P02: Multicenter open-label trial to evaluate the efficacy and safety of macimorelin acetate, single oral dose 1.0 mg/kg, as a growth hormone stimulation test (GHST) in pediatric patients with suspected growth hormone deficiency (GHD) – Phase 3 (2022).
• MK1654-PN007: A Phase 3, multicenter, randomized, partially blinded, palivizumab-controlled study to evaluate the safety, efficacy, and pharmacokinetics of MK-1654 in infants and children at increased risk for severe RSV disease (2023).
• ESCAPE: Effectiveness and Safety of Ceftazidime-Avibactam in the PaEdiatric population: a prospective observational study (2023).
• PSC-DS DG D-LACT 19: Evaluation of the effect of L. casei DG® (L. paracasei CNCM-I 1572) on the absorption of vitamin D in children. Double-blind, exploratory, randomized, controlled clinical trial (2024).
• COV2PED: Effects of SARS-CoV-2 infection on Emergency Department visits and hospitalizations in the pediatric and adolescent population: retrospective study (2021–ongoing).
• BV-2020/08: A randomised, placebo-controlled, 3-arm, double-blind, multicentre, Phase 4 study to assess the efficacy of OM-85 (Broncho-Vaxom) short- and long-term treatment vs placebo in the prevention of respiratory tract infections in children aged 6 months to 5 years with wheezing lower respiratory illness (2023–ongoing).
• 2115INF: Hypoallergenicity of a hydrolyzed rice protein-based formula in infants and young children with cow’s milk protein allergy: a randomized nutritional clinical study (2024–ongoing).
• 2204INF: Effect of a hydrolyzed rice protein-based formula on growth, tolerance, and health-related quality of life in infants with cow’s milk protein allergy (2024–ongoing).
• NIRSVR-ER: Acceptance of Nirsevimab for the prevention of respiratory syncytial virus (RSV) infection in newborns and at-risk infants: an observational study in Emilia-Romagna (2024–ongoing).
• VABOR-KIDS-01: An open-label, multicentre, single-arm study to evaluate the safety, tolerability, and pharmacokinetics of VaboremⓇ (Meropenem–Vaborbactam) in the pediatric population with complicated urinary tract infections, including acute pyelonephritis (2025–ongoing).
• THE CARICE PROJECT: COVID-19 and Acute Respiratory Infections: the clinical and epidemiological changes in the pediatric population (2025–ongoing).
• ITASAG24: National multicenter non-profit observational study comparing Italian regions with and without newborn screening for congenital adrenal hyperplasia (2025–ongoing).
• LEISH_PED: Multicenter study on pediatric leishmaniasis: clinical characteristics, epidemiology and outcomes (2025–ongoing).
• R.E.C.O.V.E.R.: Effectiveness of a multi-level strategy including anxiety screening and mobile app–based intervention for children with Long-COVID symptoms: randomized controlled study (2025–ongoing).
• THE SIS-NET PED STUDY: Clinical, microbiological and immunological characteristics of pediatric patients with community-acquired respiratory tract infections: a national multicenter prospective observational study (2025–ongoing).

Management of magazines, editorial series, encyclopedias and treatises of recognized prestige

• Collaboration in the direction of the Italian Journal of Pediatric Infectivology (from January 1, 2001 to December 31, 2010);
• Editor of Edit Symposia magazine (from 1 January 2016).

Participation in editorial committees of magazines, editorial series, encyclopedias and treaties of recognized prestige

• Member of the Pediatric Area Editorial Board (from 1 January 2001 to 31 December 2007).
• Collaboration in the management of Vaccinare Oggi & Domani (from 1 March 2002 to 31 December 2016).
• International Editor of The Pediatric Infectious Disease Journal (from May 1, 2005 to August 31,2021).
• Assistant Editor di The International Journal of Pediatric Infectious Diseases (from January 1, 2006 to December 31, 2007).
• Editorial Board Member di The International Journal of Pediatric Infectious Diseases (from January 1, 2008).
• Associate Editor of BMC Infectious Diseases (from 1 October 2009 and continues to this day).
• Associate Editor of Human Vaccines & Immunotherapeutics (from January 1, 2011 and continues today).
• Associate Editor of Journal of Clinical Virology (from January 1, 2013 and continues today).
• Editorial Board Member of PLOS One (from 1 August 2013).
• Associate Editor of Medicine (from 1 July 2014).
• Editorial Board Member of AIMS Microbiology (from May 1, 2016).
• Editorial Board Member of Npj Vaccines (from 1 July 2016).
• Editorial Board Member of Current Pharmaceutical Design (since February 2018 and continues to this day).
• Editorial Board Member of the International Journal of Environment Research and Public Health (since March 2018 and continues to this day);
• Pneumonia Editorial Board Member (since April 2019 and continues to this day).
• Editorial Board Member of Frontiers in Pediatrics (since September 2019 and continues today).
• Editorial Board Member of Expert Review in Anti-Infective Therapy (since November 2019 and continues to this day).
• Editorial Board di Pharmaceuticals (from 1 june 2020).
• Editorial Board Member di Expert Opinion on Pharmacotherapy (from May 2021).
• Editorial Board Member di Frontiers in Epidemiology (from october 2021).
• Editorial Board Member del Pediatric Respiratory Journal (from july 2022).
• Editorial Board Member di International Journal of Pediatrics and Child Health (from august 2023) e Co-Editor (from january 2024 to december 2024).
• Editorial Board di International Journal of Infectious Diseases (from january 2026).

Ongoing referee activity for scientific journals on articles related to pediatrics American Journal of Physicians; BMC Infectious Diseases; BMC Public Health; British Medical Journal; Chest; Clinical Drug Investigation; Drugs; European Journal of Pediatrics; European Respiratory Joiurnal; European Journal of Clinical Microbiology and Infectious Diseases; Human Vaccines & Immunotherapeutics; Infection; Italian Journal of Pediatrics; Journal of Chemotherapy; Journal of Clinical Virology; Journal of Infection; Journal of Pediatric Gastroenterology and Nutrition; Lancet; Lancet Infectious Diseases; Medicine; Minerva Pediatrica; Pediatric Drugs; Pediatric Health; Pediatric Pulmonology; Pediatrics; Plos One; Respiratory Medicine; Respiratory Research; The International Journal of Pediatric Infectious Diseases; The Pediatric Infectious Disease Journal; Thorax; Trends in Respiratory Medicine; Vaccine.

Assignment of official teaching or research assignments (fellowships) at universities and research institutes, foreign and international, of high qualification

• From the academic year 2009-2010 (continues to this day) she participates as a teacher at the Pediatric Infectious Diseases Diploma of the University of Oxford, UK.
• In the 2013-2014 academic year, she was called as external professor by the University of Geneva to select pediatric professors.

In the academic year 2021–2022, she was appointed as an invited professor at the Scuola Superiore Sant’Anna of Pisa.

• In the academic year 2013–2014, she was appointed as an external professor by the University of Geneva for the selection of professors in Pediatrics.
• In the academic year 2023–2024, she was appointed as an external professor by the University of Cyprus for the selection of professors in Pediatrics.

Management of high internationally qualified research bodies or institutes

• President of the Commission of the World Health Organization (WHO) for the eradication of measles and congenital rubella (from 1 January 2012 to 31 December 2015) and then Past-President of the Commission (from 1 January 2016 to 31 December 2018).

Other academic roles

• Head of the Visiting Professor program in Medicine at the University of Perugia from academic year 2016–2017 to 2018–2019, and at the University of Parma from academic year 2019–2020 to 2021–2022.
• Delegate for Third Mission at the Department of Medicine and Surgery, University of Parma (since 1 October 2021).
• Delegate for Master’s Programs at the Department of Medicine and Surgery, University of Parma (since 1 January 2024).
• Rector’s Delegate on the University–Hospital Research Board (since 3 May 2024).
• Head of training on pediatric maxi-emergencies and disaster medicine at the University of Parma for students from Myanmar (since academic year 2019–2020).
• Liaison for agreements with Emergency for the Pediatrics Residency School, University of Parma (since February 2021).
• Head of training for students and residents on pediatric emergency and urgent care, including mannequin-based simulations, PBLS-D and PALS courses (since October 2019).
• Reference pediatrician for the Giocampus Project, University of Parma (since June 2020).
• Coordinator/Reference person for the Pediatric Clinical Research Laboratory, University of Parma (since 1 September 2020).
• Member of the Working Group for Innovative Teaching, Department of Medicine and Surgery, University of Parma (since 1 September 2020).
• Member of the Healthcare Services and Relations with the National Health Service (SSN) Committee, Department of Medicine and Surgery, University of Parma (since 1 February 2021).
• Member of the Working Group for the organization and management of traineeship activities, Department of Medicine and Surgery, University of Parma (since 1 September 2020).
• Member of the Sustainability Committee, Department of Medicine and Surgery, University of Parma (since 1 March 2022).
• Member of the Interdepartmental Center for Bioethics, University of Parma (since February 2020), with the role of Head of the Post-Pandemic Unit since February 2023.
• Member of the Interdepartmental Center of Excellence Future Technology Lab, University of Parma (since April 2020).
• Member of the Interdepartmental Center of Excellence for Molecular and Translational Oncology Research, University of Parma (since June 2020), with the role of member of the Executive Board since September 2024.

Participation in academies with prestige in the sector

International academies

• Representative for the pediatric section in “Share – The IAS educational program on HIV clinical care” (from 1999 to 2002).
• Member of the Board of Directors of the European Society for Paediatric Infectious Diseases (ESPID) (from 2004 to 2007).
• Member of the Committee for Training of ESPID (2007–2013).
• Member of the Committee for Research of ESPID (2007–2013).
• Member of the Steering Committee of the Paediatric European Network for the Treatment of Infection (PENTi) (from 2008 to 2013).
• Member of the Steering Committee of the European Centre for Disease Control (ECDC) for Pneumococcal Vaccination Guidance (from 2009 to 2014).
• External Expert for the European Medicines Agency (EMA) on “Correlates for protection and serological assays on influenza vaccines” (May 2012).
• Chairperson of the Vaccine Study Group for the European Society for Clinical Microbiology and Infectious Diseases (EVASG-ESCMID; from 1 May 2013 to 30 April 2020).
• Board Member of VaccineXpert.net (since May 2014, ongoing).
• President of the World Association for Infectious Diseases and Immunological Disorders (since May 2014, ongoing).
• Member of the Independent Data Monitoring Committee (IDMC) for ertapenem (2014).
• Member of the Independent Data Monitoring Committee (IDMC) for bedaquiline (since September 2014, ongoing).
• Reference pediatrician for tuberculosis therapy for the European Respiratory Society (WHO Consilium; from 1 April 2016 to 31 December 2019).
• Member of the Global Pneumonia Prevention Coalition (from December 2015 to 31 December 2021).
• Member of the ESCMID Global Alliance for Infections in Surgery (from January 2017 to 31 December 2021).
• IDMC for Janssen on new antiviral drugs for RSV (since January 2017, ongoing).
• ECDC expert on RSV and enterovirus surveillance in Europe, 7–8 February 2017.
• Founding member of INCiPIT (Italian Network for Pediatric Clinical Trials) (since 2017).
• Member of the Steering Group on Influenza Vaccination for increasing immunization coverage across Europe (since October 2017, ongoing).
• Member of the Pneumonia Innovations Network (since January 2018, ongoing).
• External expert identified by the World Health Organization and UNESCO for the revision of the document “Advice on the use of masks for children in the context of COVID-19” (August 2020).
• Expert for the MNCAH (Maternal, Neonatal, Child and Adolescent Health) Research Network Working Groups of the WHO on COVID-19 and Educational Institutions and COVID-19 and MIS-C (since 1 October 2020, ongoing).
• Member of the Global expert panel of the TB network for the Clinical Standards on TB infection management (2021).

National academies

• Member of the Board of Directors of the Italian Society of Pediatric Infectious Diseases (from 2002 to 2005).
• Member of the Board of Directors of the Italian Society of Pediatrics – Lombardy Section (from 2004 to 2006).
• Member of the Vaccine Committee of the Italian Society of Pediatric Immunology and Allergology (from 2004 to 2018).
• Treasurer of the Italian Society of Pediatric Infectious Diseases (from 2005 to 2008).
• Scientific Secretary of the Antibiotics Commission, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan (from 2005 to 2017).
• Member of the Committee for the Prevention and Control of Hospital Infections, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan (from 2005 to 2017).
• Member of the Teaching Evaluation Committee, University of Milan (from 2005 to 2009).
• Member of the Campus Teaching Committee – Central Campus, University of Milan (from 2005 to 2009).
• Secretary of the Italian Society of Preventive and Social Pediatrics (SIPPS) (from 2008 to 2012).
• Coordinator/Reference person of the Working Group “Appropriate use of medicines” (SIPPS) (from 2008 to 2012).
• Coordinator/Reference person of the Working Group “Vaccinations” (SIPPS) (from 2008 to 2012).
• Vice-President of the Italian Society of Pediatric Infectious Diseases (from 2008 to 2011).
• Member of the Board of Directors of the Italian Society of Sexually Transmitted Diseases (from 2012 to 2021).
• President of the Italian Society of Pediatric Infectious Diseases (from 2011 to 2015).
• Member of the Board of Directors of the Italian Society of Pediatric Research (from 2012 to 2015).
• Member of the Drug Committee, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan (from 2014 to 2017).
• Member of the Healthcare Research & Pharmacoepidemiology Center (since 2016, ongoing).
• President of SIMEUP Umbria (from 2017 to 2018).
• Member of the Emilia-Romagna Region Working Group for drafting the PDTA on OSA diagnosis and treatment (from 20 November 2020 to December 2022).
• Member of the Board of Directors of the Top Italian Women Scientists (since August 2020).
• Member of the Italian Scientists Association (since January 2021).
• Member of the Board of Directors of the Italian Society of Telemedicine (SIT) – Emilia-Romagna Section since January 2021, and Vice-President from May 2022 to May 2023.
• Head of the Telepediatrics Committee of the Italian Society of Telemedicine (SIT) (since April 2022).
• Responsible for the Italian Society of Pediatrics (SIP) for selected COVID recommendations chosen by Agenas as examples of good clinical practice (February 2021).
• Testimonial for the Italian Society of Pediatrics for vaccination promotion (2021 and 2022).
• Italian testimonial of Global Wellness Day (2021).
• Coordinator of the Technical Board “Infectious Diseases and Vaccinations” of the Italian Society of Pediatrics (SIP) (since July 2021).
• Member of the group “Health education starting in schools, with activities promoting a healthy lifestyle” of the Italian Society of Pediatrics (since July 2021).
• Member of the Working Group for the NELSON Pediatrics Treatise, as editor of the sections Disorders of the Eye, The Ear, and Infectious Diseases (from 2021 to 2023).
• Member of the Technical-Scientific Committee of IPAB Opere Riunite Buon Pastore of Venice (since September 2021).
• Member of the Working Group of the Skills intelligence project of Clust-ER Industrie della Salute e del Benessere, Emilia-Romagna Region (October 2021).
• Member of the Working Group on Infectious Risk in the Emergency Department of the Italian Society of Pediatric Emergency and Urgent Medicine (SIMEUP) (since December 2021).
• President of the Italian Society of Preventive and Social Pediatrics (SIPPS) – Emilia-Romagna Section (since 1 March 2022).
• Member of the Crisis Unit of the Ministry of Health for monitoring cases of acute hepatitis of unknown etiology in pediatric age (2022).
• Member of the Scientific Committee of the National Observatory on Rare Diseases (OMaR) (since February 2023).
• National reference person for advanced simulation courses on emergency-urgent care for Accurate (since March 2023).
• Member of the jury of the EWMD TIWS 2023 “Young Promise” Call (August–September 2023).
• Member of the National Board of Directors of the Italian Society of Telemedicine (SIT) (June 2023, ongoing).
• Member of the Board of Directors of Clust-ER Health (since June 2024, ongoing).
• Coordinator of the Research Commission of the Italian Society of Pediatrics (SIP) (since June 2025)

Obtaining prizes and awards for scientific activity

• “Carlo Imperato” Award, presented by the President of the Italian Society of Pediatrics during the 58th National Congress of the Italian Society of Pediatrics (Montecatini, 28 September–2 October 2002), for the best experimental work on “Respiratory diseases in children”.
• Young Investigator Award, presented by the Chairman of the III World Congress of Pediatric Infectious Diseases (Santiago, Chile, November 19–23, 2002), for the work “Minimum protective serum concentrations of pneumococcal anti-capsular antibodies against pneumonia”.
• “George McCracken Fellowship” title, received at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (Chicago, Illinois, September 14–17, 2003).
• Young Scientist Grant, presented by the Chairman of Options for the Control of Influenza V (Okinawa, Japan, October 7–11, 2003).
• Amici di Milano Award – Medaglie d’Oro, awarded with the Silver Plaque of the President of the Italian Republic and the Silver Plaque of the President of the Lombardy Region, presented by the Mayor of Milan on 24 March 2004, as best medical researcher.
• SIP Members Award 2008, as best researcher in general and specialist pediatrics within the Italian Society of Pediatrics, awarded during the opening ceremony of the 64th Congress of the Italian Society of Pediatrics on 15 October 2008 in Genoa.
• Ambassador Award for research abroad in the medical field, presented by Hon. Maurizio Lupi on 21 May 2011 in Milan.
• Certificate of merit for commitment and professionalism shown over years dedicated to child health – Associazione Amici del Policlinico e della Mangiagalli (30 November 2014).
• Appointed ESCMID Fellow on 24 April 2017 “for outstanding service to the profession and the society”.
• Top Italian Women Scientist Award by Fondazione ONDA for scientific and communication activities (2020, 2021, 2022, 2023, 2024, 2025).
• “L’arte del bene” Award at the Festival della parola in Parma for words spoken during the COVID-19 emergency (10 July 2020).
• Award of the Associazione Giornalisti Golfisti Italiani for a pediatric endocrinology project (21 October 2021).
• Digital4Young Award for digital literacy by Parmacotto (October 2021).
• Selected among the Forbes 100 women 2022 (100 most influential women in Italy), September 2022.
• Member of the Group 2003 (since January 2024).
• Winner of the “Innovatori responsabili” Award of the Emilia-Romagna Region for the Advanced Training Course DIGItal Technology and Telemedicine for healthCARE (DIGICARE) (19/11/2025).

Other titles

• President of Amici del Bambino Malato (ABM) Onlus (from 2009 to 2019) and, since 2019, Scientific Reference person.
• Member of the Rare Diseases Unit of Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan (from January 2013 to 31 December 2017).
• Member of the GAT Sepsis, Lombardy Region (2014).
• Reviewer of CINECA research projects (since 2013, ongoing).
• Reviewer of research fellowships at the University of Padua (2014–2015), University of Insubria (2014–2015), Sapienza University of Rome (2021) and University of Rome Tor Vergata (2021).
• Reviewer of research projects for: Istituto Zooprofilattico Sperimentale delle Venezie (Legnago; 2014), Children’s Hospital of Harvard University (Boston, USA; 2015), National Science Centre of Poland (2015), Meningitis Research Foundation, University College London (2017), Czech Science Foundation (2020), Wallenberg Academy Fellows Award – Royal Swedish Academy of Sciences (2021), French National Research Agency (2021), Japan Agency for Medical Research and Development (2021), The University of Western Australia (Raine Medical Research Foundation, 2022), Swiss National Grant Foundation (March 2024), National Research Foundation of Ukraine (March 2024), French National Research Agency (May 2024).
• Reviewer for ERC Starting Grant projects (2017), RNID Fellowship Grant (May 2025), The Netherlands Organization for Health Research and Development (January 2026).
• Reviewer for projects within the internal competitive calls of the Istituto Superiore di Sanità (since 2021).
• Member of examination panels in numerous academic selection procedures for full and associate professors and university researchers.
• Member of the Commission for the National Scientific Qualification (Abilitazione Scientifica Nazionale) appointed following judicial measures (since May 2024).
• Reference person for corporate welfare projects between the University of Parma and companies in the Province of Parma (since March 2021).
• Court-appointed technical consultant (CTU) for the Court of Modena and the Court of Parma (since 2023, ongoing).

International Congress Organization

• From 2004 to 2007, she participated annually in the organization of the Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); she was Chair/President of the 31st ESPID Annual Meeting (Milan, 28 May–1 June 2013) and will be Chair/President of the 44th ESPID Annual Meeting (Bologna, 28 May–2 June 2026).
• In March 2007 and November 2009, she organized in Milan for ESPID the course “Advances in Pediatric Infectious Diseases.”
• She organized in Milan in September 2008 and September 2011 the Collaborative Research Meeting of ESPID.
• From 2009 to 2011, she organized the ESPID Research Masterclass.
• In 2015, she organized the 3rd ESCMID Conference on Vaccines (6–8 March 2015) in Lisbon, Portugal.
• In 2016, she organized the 1st Congress of the World Association for Infectious Diseases and Immunological Disorders (WAidid) in Milan (18–20 February).
• In 2017, she organized the 4th ESCMID Conference on Vaccines – New and old diseases in children and adults – unmet needs (8–10 September) in Dubrovnik, Croatia.
• In 2018, she organized the 2nd WAidid Congress in Milan (18–20 October).
• In 2019, she organized the 5th ESCMID Conference on Vaccines against respiratory infections: new insights and new vaccines in Bilbao, Spain (6–8 September).
• In 2020, she organized the WAidid Congress in virtual format (18–20 September).
• In 2022, she organized the 3rd WAidid Congress in Milan (8–10 September).
• In 2024, she was part of the Faculty organizing the 1st ESPID School on Vaccinology in Athens (16–20 September).
• In 2024, she organized the 4th WAidid Congress in Milan (28–30 November).
• Since 2024, she has been part of the Faculty organizing ESPID 2025 in Bucharest (26–30 May).
• From 1 to 5 June 2026, she will organize ESPID 2026 in Bologna.
• She is part of the Faculty that will organize ESPID 2027 in Berlin.

Organization of National Congresses

• Since 2000, she participates every year in the organization of the National Congress of Antibiotic Therapy in Pediatric Age, of which she has been co-president since 2011.
• From 2002 to 2015 she participated every year in the organization of the National Congress of the Italian Society of Pediatric Infectivology (SITIP) and was the President of the 11th SITIP National Congress in Milan in November 2011.
• From 2008 to 2012 she participated every year in the organization of the National Congress of the Italian Society of Preventive and Social Pediatrics.

I authorize the use of my personal details solely for circulation within the company according to legge 196/2003 and to Regulation EU GDPR number 2016/679 Article 13.

Parma, 16 February 2026

                                                            LA DICHIARANTE 

                                                                                       Prof.ssa Susanna Maria Roberta Esposito